Biophytis: Rises on approval to recruit more patients for COVID-19 treatment study

Biophytis SA

17/02/2021 10:39

** U.S.-listed shares of France-based biotech co  BPTS.O 
rise ~3% to $16 premarket
    ** BPTS says it received regulatory approval in France and
Belgium to recruit more patients for a study testing its drug
candidate, Sarconeos, as a potential treatment for COVID-19
associated acute respiratory failure  urn:newsml:reuters.com:*:nFWN2KN0B8
    ** Co also recruiting patients in Brazil and the U.S. for
the mid-to-late stage study, investigating the safety and
efficacy of Sarconeos on patients' respiratory function (https://bit.ly/3s1Ln0B)
    ** Full study results expected in Q2 2021, says co
    ** Sarconeos is also being developed to treat neuromuscular
diseases
    ** BPTS stock down 5.9% since market debut on Feb. 10

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))